我们研究了在护理点为肿瘤患者提供系统戒烟干预措施的成本效益。从医疗保健付款人的角度完成了决策分析模型，其中包括加拿大新不伦瑞克省吸烟患者的所有癌症病例（n = 1040）、癌症部位分层以及一年内死亡、持续吸烟和癌症治疗失败的风险。将常规护理（无戒烟支持）与标准渥太华戒烟模型 (OMSC) 干预进行比较，并与 OMSC 加无限制免费戒烟药物 (OMSC  SSM)（包括尼古丁替代疗法、伐尼克兰或安非他酮）进行比较。主要结局是每次戒烟增量成本 (ICQ) 和每次避免癌症治疗失败增量成本 (ICTFA)。标准 OMSC 的 ICQ 为 $C143，ICTFA $C1193。 OMSC  SSM 的 ICQ 为 $C503，ICTFA 为 $C5952。标准 OMSC 戒烟所需治疗 (NNT) 数为 9 例，OMSC   SSM 为 4 例；避免一次一线治疗失败所需的 NNT 为 OMSC 78 例和 OMSC   SSM 45 例。在 1000 次模拟中，两者均具有 100% 的成本效益。鉴于较高的临床效益和较低的增量成本，系统性戒烟干预措施应成为一线癌症治疗的标准组成部分。© 2024。作者。

We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care.A decision analytic model was completed from the healthcare payer's perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA).The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations.Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.© 2024. The Author(s).